TALIS BIOMEDICAL CORP (TLIS) Stock Analyst Ratings
USA - NASDAQ:TLIS - US87424L2079 - Common Stock
4.38 USD
+0.22 (+5.29%)
4.49 USD
+0.11 (+2.51%)
ChartMill assigns a Buy % Consensus number of 37% to TLIS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.1. This target is 16.44% above the current price.
TLIS was analyzed by 6 analysts. The buy percentage consensus is at 37. So analysts seem to be rather negative about TLIS.
In the previous month the buy percentage consensus was at a similar level.
TLIS was analyzed by 6 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-08-16 | BTIG | Maintains | Sell -> Sell |
| 2022-01-07 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2021-09-27 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2021-08-12 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2021-08-11 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-03-09 | BTIG | Initiate | Buy |
| 2021-03-09 | JP Morgan | Initiate | Overweight |
| 2021-03-09 | B of A Securities | Initiate | Neutral |
| 2021-03-09 | Piper Sandler | Initiate | Overweight |
TALIS BIOMEDICAL CORP / TLIS FAQ
What do analysts expect the price target to be for TALIS BIOMEDICAL CORP (TLIS)?
6 analysts have analysed TLIS and the average price target is 5.1 USD. This implies a price increase of 16.44% is expected in the next year compared to the current price of 4.38.
Can you provide the consensus rating for TALIS BIOMEDICAL CORP stock?
The consensus rating for TALIS BIOMEDICAL CORP (TLIS) is 36.6667 / 100 . This indicates that analysts generally have a negative outlook on the stock.
Can you provide the analyst count for TALIS BIOMEDICAL CORP stock?
The number of analysts covering TALIS BIOMEDICAL CORP (TLIS) is 6.